Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05988814 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Study acronym: FOLFIRINOX3 P
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Nov 1, 2028 to Jul 24, 2029 · Study sites: 0 to 1 · Start date changed from estimate of Nov 1, 2023 to Jan 24, 2024v2 Show 3 more changesShow less
    • Primary and study completion dates: Nov 1, 2028 to Jul 24, 2029
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 1, 2023 to Jan 24, 2024
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.
Trial Details
NCT Number NCT05988814
Lead Sponsor Centre Georges Francois Leclerc
Conditions Metastatic Pancreatic Cancer
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov